Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27749772 | 0.90 | KDM4E (0.43) | RXFP1ALDH1A1MEN1KMT2ASCN3A | |
| SCHEMBL13007609 | 0.89 | SCN3A (0.47) | ALDH1A1TDP1MEN1KMT2AADORA2A | |
| SCHEMBL8244471 | 0.87 | KDM4E (0.47) | ALDH1A1MEN1KMT2ASCN3ALMNA | |
| SCHEMBL8244222 | 0.85 | NPC1 (0.57) | ALDH1A1MEN1KMT2ASCN3ASMN1; SMN2 | |
| SCHEMBL13007597 | 0.84 | USP30 (0.47) | ALDH1A1TDP1MEN1KMT2AADORA2A | |
| SCHEMBL1863465 | 0.84 | SLC40A1 (0.51) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1856352 | 0.81 | KDM4E (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1855121 | 0.80 | KMT2A (0.63) | MEN1KMT2ASCN3ALMNASMN1; SMN2 | |
| SCHEMBL1857366 | 0.79 | SLC40A1 (0.45) | ALDH1A1MEN1KMT2ASCN3ASMN1; SMN2 | |
| SCHEMBL11959669 | 0.79 | MAPK1 (0.48) | ALDH1A1MEN1KMT2AADORA2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | TRPV1, TRPV2, TRPV3 | RXFP1 3134/4885ALDH1A1 3195/4885TDP1 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.